Find comprehensive SWOT and PESTLE research reports across industries globally

Holistic Analysis Customized Solutions Top Quality

Please Enter Correct Data! X
Thanks for downloading our report! X
Check your email for the requested analysis report.
Be sure to place support@swotandpestle.com on your approved senders list to prevent emails from going into spam.
Thanks for downloading our sample report! X
Check your email for the requested sample analysis report.
You can also download it here.
Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Great quality, Affordable pricing X

As a leading strategy research portal we invest deep to produce imperial quality reports that can help corporate professionals, academicians and students take their research forward and set a benchmark for high standard business research. The cost for reports has been kept minimal to just cover our operational and maintenance costs although the mission is not to reap monetary benefits. We look forward to your support.

Pfizer SWOT & PESTLE Analysis

ID : 5281753 | Jun 2017

OVERVIEW

Name of the Company: Pfizer

Business Sector: Pharma

Operating Geography: North America, USA, Global

About the Company: Pfizer is an American pharmaceutical giant headquartered in New York. It was founded in 1849 by Charles Pfizer and Charles F. Erhart. Pfizer is into research, development and production of drugs and vaccines, and has nine broad operating divisions.

Revenue: 48.9 Billion USD - FY 2015

SWOT & PESTLE Analysis

The SWOT analysis for Pfizer is presented below:
Strengths
Weaknesses
1. Strong brand name
2. Extensive portfolio with several bestselling drugs
3. Focus on R&D and innovation
4. Ranked high on corporate responsibility and sustainability indices
5. High profitability and huge cash reserves
1. Negative publicity due to tax scandals
2. Drug testing debacles
3. Tough competition from generic drug makers
4. Allegations of illegal marketing
5. Failed mergers and acquisitions
Opportunities
Threats
1. Increasing awareness of health related issues in developing countries
2. Potential partnerships with governments
3. Collaborative R&D with pharmaceutical companies in developing countries
4. Focus on sustainability
1. Unfavourable patent laws
2. Stringent regulatory environment
3. Threat of drug-resistant strains in the future
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

Safe and secure payments

* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."

Strengths

1. Strong brand name: Pfizer has a history of 160+ years of experience in the pharmaceutical industry and therefore, brand recall is considerably strong.

2. Extensive portfolio with several bestselling drugs: Pfizer has pioneered in the development as well as production of several best-selling, blockbuster drugs, such as Atorvastatin and Zoloft.

3. Focus on R&D and innovation: Pfizer’s R&D focus has led to the existence of the large and ever-increasing number of patents to its credit.

4. Ranked high on corporate responsibility and sustainability indices: Pfizer is committed to the reduction of greenhouse gas emissions and also has active corporate responsibility initiatives across the globe.

5. High profitability and huge cash reserves: Pfizer has historically been a huge profit maker with abundant cash reserves, and has grown inorganically as well as organically.

Weaknesses

1. Negative publicity due to tax scandals: Pfizer had been involved in several scandals, the most recent being the issue of tax inversion to UK, which made the company cancel its ambitious plans to merge with an Irish drug company.

2. Drug testing debacles: Pfizer has had several cases of failed or scrapped drug tests, and FDA interventions due to breach of regulations.

3. Tough competition from generic drug makers: Pfizer currently faces huge issues due to the laws protecting generic drug manufacturers in developing economies to provide affordable healthcare to the poor.

4. Allegations of illegal marketing: Pfizer has been involved in several cases of illegal marketing of drugs for purposes other than the intended purposes.

5. Failed mergers and acquisitions: Pfizer has had enormous inorganic growth, but not all of the mergers and acquisitions in the past have been profitable for the company.

Opportunities

1. Increasing awareness of health related issues in developing countries: Due to the fact that people in developing or emerging economies are becoming aware of health and sanitation issues, Pfizer has a huge potential for marketing their products in these countries.

2. Potential partnerships with governments: Pfizer can seek to partner with governments in developing countries to boost health related awareness campaigns, thereby creating demand while also giving back to the society.

3. Collaborative R&D with pharmaceutical companies in developing countries: Pfizer can explore untapped markets by signing collaborative research agreements with pharmaceutical companies in developing countries, which are now centres of low-cost innovation.

4. Focus on sustainability: The global trend of focusing on long-term, sustainable business goals can be leveraged by Pfizer, which is already a pioneer in this direction.

Threats

1. Unfavourable patent laws: Governments in third world countries supporting local pharmaceutical companies in the development of cheap generic drugs, coupled with unfavourable patent laws can prove to be a major challenge to large pharmaceutical companies like Pfizer who recover their R&D costs by being the sole manufacturer of their patented drugs.

2. Stringent regulatory environment: Of late, FDA and other bodies have made the rules that apply to drug testing and allied fields extremely stringent due to hue and cry from human rights activists from across the globe, especially against testing of drugs on people from poorer countries.

3. Threat of drug-resistant strains in the future: There is always the risk of disease causing strains developing resistance against existing drugs, and this entails huge R&D costs for the development of new and better drugs to combat these mutant strains.

Pfizer SWOT analysis has been conducted by Neeraja R Venu and reviewed by senior analysts from Barakaat Consulting.

References

[1] Pfizer home page: http://www.pfizer.com/

[2] NY Times – Pfizer – Allergan merger: http://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html?_r=1

[3] Money Control: http://stat1.moneycontrol.com/Dow_Jones_Industrial_Average_Historical_Components.pdf

[4] Reuters: http://www.reuters.com/article/us-allergan-m-a-pfizer-idUSKBN0TB0UT20151124

[5] FDA: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886.htm

[6] BBC: http://www.bbc.com/news/business-34900344

[7] Bloomberg: http://www.bloomberg.com/news/articles/2015-11-22/pfizer-allergan-said-to-be-close-to-150-billion-merger

[8] Corporate Integrity Agreement: https://oig.hhs.gov/fraud/cia/agreements/pfizer_inc.pdf

[9] Legal Information Institute: https://www.law.cornell.edu/supct/html/04-108.ZO.html

Safe and secure payments

* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."

Copyrights and Disclaimer

Copyright of Pfizer SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions page for usage guidelines.